Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.